Contribute Try STAT+ Today

Syndax Pharmaceuticals said Tuesday that its genetically targeted cancer drug induced complete remissions in patients with advanced leukemia, although questions may linger about a heart-related side effect that limited dosing.

The Syndax drug, a once-daily pill called SNDX-5613, belongs to an emerging class of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined leukemia that do not respond well to currently approved medicines. These drugs work by blocking the interaction of two proteins that prevents bone marrow cells from developing or differentiating into healthy cells.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.